Edwards Lifesciences Guides Q3 Adj EPS to $0.71-$0.77
EW sits 25% above its 52-week low of $72.3.
Summary
Edwards Lifesciences issued Q3 adjusted EPS guidance of $0.71-$0.77, providing a concrete range for the first time. This follows a strong Q1 report and the recent appointment of a new CFO, Theodora Mistras, from Viatris. The guidance gives traders a benchmark to gauge the company's near-term earnings trajectory amid ongoing IRS tax disputes and a recent FTC penalty. No consensus estimate is provided for comparison, but the range itself is the new information that will drive positioning ahead of the quarter.
At the time of this announcement, EW was trading at $90.04 on NYSE in the Life Sciences sector, with a market capitalization of approximately $48.3B. The 52-week trading range was $72.30 to $96.29. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.